Yuhki Koga
Overview
Explore the profile of Yuhki Koga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asano T, Morimoto A, Nakazawa A, Ueda T, Ogawa C, Sakata N, et al.
Int J Hematol
. 2025 Mar;
PMID: 40063331
Background: Rosai-Dorfman-Destombes disease (RDD) is a rare form of histiocytosis, characterized by the accumulation of S100 protein-positive and CD1a-negative histiocytes with emperipolesis. Recently, oncogenic mutations in mitogen-activated protein kinase pathway...
2.
Yamamoto S, Sanefuji M, Inoue H, Inoue M, Shimo Y, Toya S, et al.
Early Hum Dev
. 2025 Jan;
201:106195.
PMID: 39799803
Background: Many studies have indicated an association between maternal occupational exposure to hazardous agents, such as anticancer drugs and ionizing radiation, and an increased risk of adverse pregnancy outcomes, including...
3.
Okuzono S, Yamada T, Motomura Y, Kanemasa H, Ishimura M, Koga Y, et al.
Ther Drug Monit
. 2025 Jan;
PMID: 39792008
Background: Therapeutic drug monitoring-informed teicoplanin dosage adjustments are recommended for safe and effective use. The authors' group previously reported that only half of children reached the recommended blood concentration range...
4.
Suzuki M, Koga Y, Kawasaki T, Ueda T, Yamamoto S, Goto H, et al.
Pediatr Blood Cancer
. 2025 Jan;
72(3):e31510.
PMID: 39762715
Programs allowing access to investigational drugs and off-label drug use for serious diseases have often been applied to pediatric cancers. A clinical study conducted under the Japanese "Patient-Proposed Healthcare Services"...
5.
Kato I, Tomizawa D, Kato M, Hirabayashi S, Manabe A, Irie M, et al.
Transplant Cell Ther
. 2024 Dec;
31(2):86-96.
PMID: 39617098
Chimeric antigen receptor (CAR) T cells are a major new treatment option for children, adolescents, and young adults (CAYA) patients with relapsed and refractory (R/R) B cell acute lymphoblastic leukemia...
6.
Goto H, Oba U, Ueda T, Yamamoto S, Inoue M, Shimo Y, et al.
Pediatr Blood Cancer
. 2024 Sep;
71(12):e31331.
PMID: 39289887
Background: Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening complications of hematopoietic cell transplantation (HCT). Methods: We studied the impact of early defibrotide (DF) therapy...
7.
Sakaguchi H, Taga T, Ishida H, Hama A, Okamoto Y, Sano H, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1621-1624.
PMID: 39174743
No abstract available.
8.
Nakashima K, Imai T, Shiraishi A, Unose R, Goto H, Nagatomo Y, et al.
Clin Exp Immunol
. 2024 Jun;
217(3):291-299.
PMID: 38916251
The clinical spectrum of Down syndrome (DS) ranges from congenital malformations to premature aging and early-onset senescence. Excessive immunoreactivity and oxidative stress are thought to accelerate the pace of aging...
9.
Noda Y, Koga Y, Yamamura K, Miyata J, Hamada Y, Ohga S
Int J Hyg Environ Health
. 2024 Jun;
260:114402.
PMID: 38870739
The exposure of family caregivers to anticancer drugs for pediatric patients with malignancy is a potential health risk that needs to be minimized. We monitored the amount of cyclophosphamide (CPM)...
10.
Ishida H, Kawahara Y, Tomizawa D, Okamoto Y, Hama A, Cho Y, et al.
J Hematol Oncol
. 2024 Apr;
17(1):24.
PMID: 38679709
Although killer Ig-like receptor ligands (KIR-L) mismatch has been associated with alloreactive natural killer cell activity and potent graft-versus-leukemia (GVL) effect among adults with acute myeloid leukemia (AML), its role...